Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (LSE:AZN) reported results from a late-stage clinical trial evaluating a combination of Amgen’s Imdelltra and AstraZeneca’s Imfinzi as a maintenance treatment for extensive-stage small-cell lung cancer.
The trial compared Imdelltra plus Imfinzi with Imfinzi alone in patients whose disease had not progressed following standard initial therapy.
According to the companies, the combination demonstrated improvements in overall survival, progression-free survival and response rate compared with Imfinzi alone. They also said no new safety concerns were identified during the trial.
Imdelltra received accelerated approval from the U.S. Food and Drug Administration in 2024 for extensive-stage small-cell lung cancer, followed by traditional approval in 2025.
The treatment generated $513 million in sales for Amgen last year. Cancer treatments account for approximately 23% of the company’s total revenue.
Imdelltra is part of Amgen’s portfolio of bispecific antibodies. These treatments are designed to connect cancer cells with immune cells, allowing the immune system to target the cancer cells.
Leave a Reply